

EULAR COVAX Registry

for rheumatologists and other clinicians


The EULAR COVAX Registry is a European paediatric and adult registry to monitor and report on outcomes of COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases (RMDs).

Data extract: 05 October 2021

Total number of patients to 05 October 2021: 6589

To date there have been 6589 patients reported to the EULAR COVAX registry from 30 countries.

Figure 1: Cumulative number of reports to the database and cumulative cases by date of first vaccination, from December 2020 until 05 October 2021 (current data extract).



EULAR COVAX Registry

for rheumatologists and other clinicians

Table 1: Patient Demographics

		All patients
Total number		6589
<hr/>		
Gender N (%)	Female	4569 (69%)
	Male	1967 (30%)
	Other / Unknown	53 (1%)
<hr/>		
Age	Median (IQR)	62 (51 - 73)
	Range (min to max)	0 to 98
<hr/>		
Age categories (years) N (%)	<18	23 (<1%)
	18-40	751 (11%)
	41-60	2270 (34%)
	61-more	3545 (54%)
<hr/>		
Country N (%)	Albania	1 (<1%)
	Australia	1 (<1%)
	Austria	16 (<1%)
	Belgium	251 (4%)
	Croatia	10 (<1%)
	Czech Republic	1 (<1%)
	Estonia	1 (<1%)
	France	2542 (39%)
	Germany	36 (1%)
	Greece	38 (1%)
	Hungary	20 (<1%)
	Italy	1219 (19%)
	Latvia	392 (6%)
	Lithuania	3 (<1%)
	Luxembourg	3 (<1%)
	Monaco	334 (5%)
	Netherlands	6 (<1%)
	Portugal	754 (11%)
	Republic of Ireland	84 (1%)
	Republic of Moldova	1 (<1%)
Romania	67 (1%)	
Russia	6 (<1%)	
Slovak Republic	355 (5%)	
Slovenia	14 (<1%)	

EULAR COVAX Registry

for rheumatologists and other clinicians

Spain	227 (3%)
Switzerland	6 (<1%)
Turkey	100 (2%)
Ukraine	2 (<1%)
United Kingdom	86 (1%)
United States of America	13 (<1%)

Table 2: Disease information

		All Patients
Primary Rheumatology Diagnosis N (%)	Rheumatoid Arthritis (RA)	2142 (33%)
	Spondyloarthritis (including Axial spondyloarthritis, other spondyloarthritis)	917 (14%)
	Psoriatic arthritis	656 (10%)
	Systemic Lupus Erythematosus	444 (7%)
	Osteoarthritis	332 (5%)
	Polymyalgia rheumatica	276 (4%)
	Sjogrens syndrome	270 (4%)
	Systemic sclerosis	182 (3%)
	Large vessel vasculitis (Giant cell arteritis, Takayasu arteritis)	177 (3%)
	Osteoporosis	158 (2%)
	ANCA-associated vasculitis (e.g., GPA, EGPA)	142 (2%)
	Gout	91 (1%)
	Inflammatory myopathy (e.g. dermatomyositis, polymyositis)	82 (1%)
	Other inflammatory arthritis	81 (1%)
	Psoriasis	66 (1%)
	Sarcoidosis	65 (1%)
	Fibromyalgia	63 (1%)
	Juvenile idiopathic arthritis (not systemic)	59 (1%)
	Other mechanical RMD (e.g. tendinopathies, peri- articular disease)	59 (1%)
	Undifferentiated connective tissue disease	54 (1%)
Mixed connective tissue disease	42 (1%)	
Behcets	40 (1%)	
Anti-phospholipid antibody syndrome	33 (<1%)	
Other vasculitis	29 (<1%)	
Chronic mechanical back pain	22 (<1%)	
IgG4-related disease	16 (<1%)	
Monogenic autoinflammatory syndrome	15 (<1%)	
Radiculopathy or regional pain syndrome	14 (<1%)	

EULAR COVAX Registry

for rheumatologists and other clinicians

Medium-vessel vasculitis	14 (<1%)
Non-monogenic autoinflammatory syndrome	13 (<1%)
Juvenile idiopathic arthritis (systemic)	13 (<1%)
Immune complex small-vessel vasculitis	9 (<1%)
Relapsing polychondritis	9 (<1%)
Chronic recurrent multifocal osteomyelitis	3 (<1%)
Ehlers-Danlos Syndromes (EDS)	1 (<1%)

COVID-19 Vaccine Type N (%)	Pfizer/BioNTech	4558 (69%)
	AstraZeneca/Oxford	1164 (18%)
	Moderna	586 (9%)
	Unknown	127 (2%)
	Janssen/Johnson & Johnson	76 (1%)
	CoronaVac/Sinovac	67 (1%)
	Sputnik V	7 (<1%)
	Other	4 (<1%)

COVID-19 Vaccine Doses N (%)	One	1473 (22%)
	Two	5025 (76%)
	Three	81 (1%)
	Unknown	7 (<1%)

Note: 3 patients are missing vaccine dose data.

Patient diagnosed with COVID-19 after vaccination N (%)	Yes	74 (1%)
	No	6187 (94%)
	Unknown	74 (1%)
	Missing	254 (4%)

Rheumatic disease flare following vaccination N (%)	Yes	283 (4%)
	No	5494 (83%)
	Unknown	808 (12%)
	Missing	4 (<1%)

Adverse event following vaccination N (%)	Yes	2475 (38%)
	No	3977 (60%)
	Unknown	132 (2%)
	Missing	5 (<1%)

EULAR COVAX Registry

for rheumatologists and other clinicians

Early adverse event N(%)	Pain at the site of injection	1180 (18%)
	Redness at the site of injection	84 (1%)
	Swelling at the site of injection	88 (1%)
	Generalized muscle pain	445 (7%)
	Generalized joint pain	235 (4%)
	Headache	423 (6%)
	Fever	578 (9%)
	Chills	197 (3%)
	Fatigue	771 (12%)
	Vomiting	80 (1%)
	Diarrhoea	50 (1%)
<hr/>		
Adverse events of special interest N (%)	Immunologic – Anaphylaxis	2 (<1%)
	Immunologic – Vasculitides	3 (<1%)
	Immunologic – Arthritis	13 (<1%)
	Cardiac – Coronary artery disease	2 (<1%)
	Cardiac – Arrhythmia	6 (<1%)
	Cardiac – Myocarditis, pericarditis	1 (<1%)
	Haematologic – Thrombocytopenia	2 (<1%)
	Haematologic – Deep vein thrombosis	2 (<1%)
	Haematologic – Hemorrhagic disease	1 (<1%)
	Gastrointestinal – Liver injury	3 (<1%)
	Neurologic – Anosmia, ageusia	1 (<1%)
	Dermatologic – Single organ cutaneous vasculitis	1 (<1%)
	Dermatologic – Erythema multiforme	1 (<1%)
Other	181 (3%)	

Disclaimer

The EULAR COVAX Database is based on doctors voluntarily reporting cases, meaning that patients included do not necessarily represent the majority of patients with RMDs who have had a COVID-19 vaccination, but those who their doctors reported data to the database. Additionally, this database does not account for non-vaccinated patients. Therefore, results cannot be directly extrapolated to the entire population of patients with RMDs, and should be interpreted cautiously. For research purposes and proper considerations, this data requires adequate analysis, further adjustments and stratifications.